Skip to main content
1738 search results for:

Enzalutamide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Enzalutamide | News

    Enzalutamide

    Lack of efficacy
  2. Open Access 12-04-2024 | Enzalutamide | Online First

    Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

    Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and a strong inducer of CYP3A4. It was also …

  3. 01-03-2024 | Enzalutamide | News

    Enzalutamide

    Lack of efficacy
  4. Open Access 01-12-2024 | Enzalutamide | OriginalPaper

    Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

    Extensive exploration of the molecular subtypes of triple-negative breast cancer (TNBC) is critical for advancing precision medicine. Notably, the luminal androgen receptor (LAR) subtype has attracted attention for targeted treatment combining …

  5. Open Access 01-12-2024 | Enzalutamide | OriginalPaper

    Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran

    Prostate cancer is the second most common cancer in men worldwide [ 1 ]. According to the GLOBOCAN report, 14,090 new cases of cancer occur in the world each year and the annual rate of death from this disease in 8,202 people around the world. In …

  6. 14-11-2023 | Androgens | OriginalPaper

    Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide

    Prostate cancer is the second most frequent cancer diagnosed in men, and accounts for one-fifth of cancer associated deaths worldwide. Despite the availability of effective prostate cancer therapies, if it is not cured by radical local treatment …

  7. 01-11-2023 | Heart Failure | News

    Enzalutamide/relugolix

    Heart-disorders: 4 case reports
  8. 29-09-2023 | Prostate Cancer | OriginalPaper

    Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Prostate cancer is the second commonly diagnosed cancer in men worldwide. In an advanced setting, androgen deprivation therapy can be used with or without treatments targeting androgen pathways or docetaxel. Many patients progress while receiving …

  9. Open Access 01-12-2023 | Enzalutamide | OriginalPaper

    Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events

    Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options, but the more advanced stages require …

  10. 26-10-2023 | Prostate Cancer | News | Article
    ESMO 2023

    Added value for combination radium-223 and enzalutamide in mCRPC

    Combination treatment with radium-223 and enzalutamide appears to have added value for patients with metastatic castration-resistant prostate cancer in the REASSURE study.

  11. 20-10-2023 | Prostate Cancer | News | Article

    Enzalutamide use supported for biochemically recurrent prostate cancer

    Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

  12. Open Access 01-12-2023 | Prostate Cancer | OriginalPaper

    Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

    Androgen deprivation therapy (ADT) has been the fundamental strategy for the treatment of metastatic prostate cancer. However, almost all patients acquired resistance to ADT after years of treatment, known as castration-resistant prostate cancer …

  13. 01-03-2023 | Generalized Seizure | News

    Enzalutamide

    Generalised seizure: case report
  14. 01-02-2023 | Enzalutamide | News

    Enzalutamide

    Congestive heart failure: case report
  15. Open Access 01-12-2023 | Prostate Cancer | OriginalPaper

    Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

    A recent clinical trial revealed the efficacy of abiraterone acetate (ABI), enzalutamide (ENZ), Radium-223 (Ra-223), and cabazitaxel in addition to docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) patients [ 1 – 3 …

  16. Open Access 10-05-2023 | Prostate Cancer | OriginalPaper

    Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer

    With an incidence of 63.4 per 100,000 men, prostate cancer is the most common type of cancer among men worldwide [ 1 ]. Approximately 90% of the patients with metastatic prostate carcinoma will develop bone metastases, which can cause severe pain [ …2

  17. 01-01-2023 | Carvedilol | News

    Enzalutamide/leuprorelin/sipuleucel-t

    Inflammatory cardiomyopathy: case report
  18. Open Access 01-12-2023 | Prostate Cancer | OriginalPaper

    Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

    Almost 1.5 million men were diagnosed with prostate cancer and more than 370,000 died of this disease in 2020, worldwide [ 1 ]. Metastatic castration-resistant prostate cancer is a lethal state of this disease and typically leads to death in …

  19. 01-10-2022 | Enzalutamide | News

    Enzalutamide

    Treatment failure: 3 case reports
  20. Open Access 01-12-2022 | Prostate Cancer | OriginalPaper

    Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

    With the widespread use of prostate-specific antigen (PSA) testing, the number of localized prostate cancer (PC) cases without metastasis are increasing in Japan; it has been reported to constitute more than 85% of PC cases [ 1 ]. The standard …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.